US FDA Touts Value Of Phase III Trials Amid Presidential Transition
As future of agency remains uncertain, report makes the case for strict approval standards.
You may also be interested in...
US FDA advisory committee will weigh in on clinical development plan for SA4Ag, an S. aureus vaccine for prophylactic use, including whether safety and efficacy data from an ongoing, Phase II trial in spinal surgery patients are generalizable to other elective orthopedic surgical populations.
Agency memo on manufacturer communications about unapproved uses says new court rulings and studies on off-label uses and adverse reactions support restrictions; whether agency’s new leadership has the same view remains to be seen.
Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.